Closed System Transfer Devices (CSTD) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Closed System Transfer Devices (CSTD) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The closed system transfer devices are expected to project a CAGR of 18% over the forecast period (2022-2027).

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. However, with the advent of the COVID-19 infection, large-scale vaccinations were performed all over the world, which majorly benefitted the closed system transfer devices market. An article titled “A Needle-Free Jet Injection System for Controlled Release and Repeated Biopharmaceutical Delivery” published in the journal of Pharmaceuticals in November 2021 studied the successful design and working model of an air-driven needle-free jet injector, which is a type of needleless closed system transfer device, for use during the large-scale COVID-19 vaccinations. The model had a drug delivery efficiency of 96.7% for 0.2 mL/shot injections and 97.8% drug transfer efficiency at 0.5 mL/shot. The proposed model could be used commercially, as the WHO guidelines for injection devices require 86% or higher accuracy. Such developments in closed system transfer devices are likely to add to the growth of the market over the forecast period.

The increasing prevalence of cancer around the world and the rise in the number of oncology product approvals are major factors attributing to the growth of the studied market. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. ​The huge number of people affected by cancer, creating a demand for innovative drug delivery technologies is expected to add to the growth of the closed system transfer devices market.

Limiting the exposure to hazardous drugs/chemicals is important due to the potential harm that might cause to healthcare workers and patients in healthcare/clinical setups. Due to the increased incidence of hazardous drug exposures in many countries, the regulatory authorities have taken many initiatives to ensure the safety of patients and healthcare workers. Owing to the factors such as growing awareness regarding usage of closed system transfer devices and increased oncology drug approvals global closed system transfer devices (CSTD) market is expected to grow significantly. Furthermore, the technological advancements in closed system transfer devices anticipated to boost the market growth.

However, the high cost involved in the implementation of closed system transfer devices directly increases the cost of treatment/products. Furthermore, improper regulatory guidelines in developing and underdeveloped countries may hamper market growth over the forecast period.

Key Market TrendsNeedleless System Transfer Devices Anticipated to Grow at Significant Rates during the Forecast Period

The Needleless system segment is anticipated to grow at notable rates owing to the advantages such as needle-free transfer of the medication, new product launches, and safety. The advantages such as ease of use, and low risk of contamination ensure the safety anticipated to increase the usage of the needleless transfer devices over the forecast period.

There has been a rise in the prevalence of chronic diseases such as diabetes, cancer, heart disease, and stroke. Other lifestyle diseases such as chronic lung disease, chronic kidney disease, and Alzheimer’s disease have also been on the rise over the past decade. In 2021, the Center for Disease Control and Prevention has listed that in the United States, six in ten adults have at least one chronic disease and four in ten adults have two or more. The increasing prevalence of such chronic diseases has also augmented the innovations in the needleless drug delivery system.

The large prevalence of chronic diseases such as cancer and diabetes is expected to propel the growth of the market over the forecast period. The IDF Diabetes Atlas Tenth edition by the International Diabetes Federation showed that around 537 million adults are affected by diabetes as of 2021. The number of cases is projected to rise to 643 million by 2030 and to 783 million by 2045. The type 1 diabetic patients require insulin to be injected for controlling the blood sugar levels. Companies such as Insujet provide needle-free solution for insulin therapy, which are likely to add to the growth of the needleless systems segment over the forecast period.

Moreover, the growing incidence of cancer cases and awareness regarding the usage of closed system transfer devices anticipated to fuel the market growth.

North America Expected to have Significant Market Share over the Forecast Period.

North America is expected to have a significant market share in closed system transfer devices market. The growth is attributed to initiatives taken by the U.S. Food and Drug Administration and other regulatory bodies in North America to ensure patient safety coupled with the increasing number of oncology drug approvals in the region. The Asia Pacific region is projected to have a notable growth rate owing to the factors such as the increase in cancer research, the growing prevalence of cancer in developing and underdeveloped countries of the region. Furthermore, the usage of the closed system transfer devices to combat the hazardous drugs in the region and continuous efforts by the public and private organizations are anticipated to boost regional growth.

The rising number of chronic disease cases in the North American region is adding to the growth of the closed system transfer devices market.​ Cancer is one of the top ten leading causes of death in the United States. According to the GLOBOCAN 2020 report, the total number of people in the United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. ​According to the National Diabetes Statistics Report, in 2020, around 37.3 million people in the United States were found to have diabetes; around 96 million adults were found to have pre-diabetes. ​The National Kidney Foundation in 2020 has estimated that about 36 million adults in the US have chronic kidney diseases. ​A report by the Center for Disease prevention and Control in 2020 showed that around 15.7 million Americans are affected by chronic lower respiratory Disease.​ The large population affected by the chronic diseases and the increase in the necessity of novel drug delivery systems are expected to significantly boost the growth of the market.

Several key market players in the North American region are also aiding the market growth. For instance, in December 2021, B. Braun Medical Inc. launched the OnGuard 2 CSTD in the United States. The OnGuard 2 incorporated all of the current advantages of the previously launched OnGuard while offering upgraded materials and enhanced features to improve its usability.Such product launches are expected to propel the market growth over the forecast period.

Competitive Landscape

Global transfer membrane market is moderately consolidated and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Becton, Dickinson and Company, ICU Medical, Inc., Caragen Ltd., Baxter International Inc. and B. Braun Melsungen AG among others

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.